A Patenting Perspective on Human Neutrophil Elastase (HNE) Inhibitors (2014-2018) and Their Therapeutic Applications

Overview

Journal Expert Opin Ther Pat

Publisher Informa Healthcare

Date 2019 Jun 18

PMID 31204543

Citations 32

Authors

L Crocetti

M T Quinn

I A Schepetkin

M P Giovannoni

Affiliations

Soon will be listed here.

Abstract

Introduction: Human neutrophil elastase (HNE) is involved in a variety of serious chronic diseases, especially cardiopulmonary pathologies. For this reason, the regulation of HNE activity represents a promising therapeutic approach, which is evident by the development of a number of new and selective HNE inhibitors, both in the academic and pharmaceutical environments.

Areas Covered: The present review analyzes and summarizes the patent literature regarding human neutrophil elastase inhibitors for the treatment of cardiopulmonary diseases over 2014-2018.

Expert Opinion: HNE is an interesting and defined target to treat various inflammatory diseases, including a number of cardiopulmonary pathologies. The research in this field is quite active, and a number of HNE inhibitors are currently in various stages of clinical development. In addition, new opportunities for HNE inhibitor development stem from recent studies demonstrating the involvement of HNE in many other inflammatory pathologies, including rheumatoid arthritis, inflammatory bowel disease, skin diseases, and cancer. Furthermore, the development of dual HNE/proteinase 3 inhibitors is being pursued as an innovative approach for the treatment of neutrophilic inflammatory diseases. Thus, these new developments will likely stimulate new and increased interest in this important therapeutic target and for the development of novel and selective HNE inhibitors.

Citing Articles

Neutrophil extracellular traps in homeostasis and disease.

Wang H, Kim S, Lei Y, Wang S, Wang H, Huang H Signal Transduct Target Ther. 2024; 9(1):235.

PMID: 39300084 PMC: 11415080. DOI: 10.1038/s41392-024-01933-x.

Human Neutrophil Elastase: Characterization of Intra- vs. Extracellular Inhibition.

Birk D, Siepmann E, Simon S, Sommerhoff C Int J Mol Sci. 2024; 25(14).

PMID: 39063160 PMC: 11276905. DOI: 10.3390/ijms25147917.

Natural Compounds as Protease Inhibitors in Therapeutic Focus on Cancer Therapy.

Kakali B Anticancer Agents Med Chem. 2024; 24(16):1167-1181.

PMID: 38988167 DOI: 10.2174/0118715206303964240708095110.

Expression and purification of human neutrophil proteinase 3 from insect cells and characterization of ligand binding.

Khorsand F, Haug B, Kursula I, Reuter N, Brenk R PLoS One. 2024; 19(6):e0294827.

PMID: 38917138 PMC: 11198849. DOI: 10.1371/journal.pone.0294827.

Ebselen analogues with dual human neutrophil elastase (HNE) inhibitory and antiradical activity.

Crocetti L, Catarzi F, Giovannoni M, Vergelli C, Bartolucci G, Pallecchi M RSC Med Chem. 2024; 15(4):1247-1257.

PMID: 38665832 PMC: 11042244. DOI: 10.1039/d3md00736g.

References

Wang Z, Chen F, Zhai R, Zhang L, Su L, Lin X . Plasma neutrophil elastase and elafin imbalance is associated with acute respiratory distress syndrome (ARDS) development. PLoS One. 2009; 4(2):e4380. PMC: 2633615. DOI: 10.1371/journal.pone.0004380. View

Cawston T, Young D . Proteinases involved in matrix turnover during cartilage and bone breakdown. Cell Tissue Res. 2009; 339(1):221-35. DOI: 10.1007/s00441-009-0887-6. View

Meyer-Hoffert U, Wingertszahn J, Wiedow O . Human leukocyte elastase induces keratinocyte proliferation by epidermal growth factor receptor activation. J Invest Dermatol. 2004; 123(2):338-45. DOI: 10.1111/j.0022-202X.2004.23202.x. View

Schaaf B, Wieghorst A, Aries S, Dalhoff K, Braun J . Neutrophil inflammation and activation in bronchiectasis: comparison with pneumonia and idiopathic pulmonary fibrosis. Respiration. 2000; 67(1):52-9. DOI: 10.1159/000029463. View

Reeves E, Lu H, Jacobs H, Messina C, Bolsover S, Gabella G . Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature. 2002; 416(6878):291-7. DOI: 10.1038/416291a. View

Hermant B, Bibert S, Concord E, Dublet B, Weidenhaupt M, Vernet T . Identification of proteases involved in the proteolysis of vascular endothelium cadherin during neutrophil transmigration. J Biol Chem. 2003; 278(16):14002-12. DOI: 10.1074/jbc.M300351200. View

Allen D, Tracy P . Human coagulation factor V is activated to the functional cofactor by elastase and cathepsin G expressed at the monocyte surface. J Biol Chem. 1995; 270(3):1408-15. DOI: 10.1074/jbc.270.3.1408. View

von Nussbaum F, Li V, Meibom D, Anlauf S, Bechem M, Delbeck M . Potent and Selective Human Neutrophil Elastase Inhibitors with Novel Equatorial Ring Topology: in vivo Efficacy of the Polar Pyrimidopyridazine BAY-8040 in a Pulmonary Arterial Hypertension Rat Model. ChemMedChem. 2015; 11(2):199-206. DOI: 10.1002/cmdc.201500269. View

Marvel D, Gabrilovich D . Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015; 125(9):3356-64. PMC: 4588239. DOI: 10.1172/JCI80005. View

10.

Hedstrom L . Serine protease mechanism and specificity. Chem Rev. 2002; 102(12):4501-24. DOI: 10.1021/cr000033x. View

11.

Cooley J, Takayama T, Shapiro S, Schechter N, Remold-ODonnell E . The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites. Biochemistry. 2001; 40(51):15762-70. DOI: 10.1021/bi0113925. View

12.

Weyer A, Stucky C . Repurposing a leukocyte elastase inhibitor for neuropathic pain. Nat Med. 2015; 21(5):429-30. DOI: 10.1038/nm.3861. View

13.

Senior R, Campbell E . Neutral proteinases from human inflammatory cells. A critical review of their role in extracellular matrix degradation. Clin Lab Med. 1983; 3(4):645-66. View

14.

Miravitlles M . Alpha-1-antitrypsin and other proteinase inhibitors. Curr Opin Pharmacol. 2012; 12(3):309-14. DOI: 10.1016/j.coph.2012.02.004. View

15.

Crocetti L, Bartolucci G, Cilibrizzi A, Giovannoni M, Guerrini G, Iacovone A . Synthesis and analytical characterization of new thiazol-2-(3H)-ones as human neutrophil elastase (HNE) inhibitors. Chem Cent J. 2017; 11(1):127. PMC: 5718994. DOI: 10.1186/s13065-017-0358-1. View

16.

Giovannoni M, Schepetkin I, Crocetti L, Ciciani G, Cilibrizzi A, Guerrini G . Cinnoline derivatives as human neutrophil elastase inhibitors. J Enzyme Inhib Med Chem. 2015; 31(4):628-39. PMC: 4721940. DOI: 10.3109/14756366.2015.1057718. View

17.

Cowburn A, Condliffe A, Farahi N, Summers C, Chilvers E . Advances in neutrophil biology: clinical implications. Chest. 2008; 134(3):606-612. PMC: 2827863. DOI: 10.1378/chest.08-0422. View

18.

Pham C . Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol. 2006; 6(7):541-50. DOI: 10.1038/nri1841. View

19.

Lerman I, Garcia-Hernandez M, Rangel-Moreno J, Chiriboga L, Pan C, Nastiuk K . Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase. Mol Cancer Res. 2017; 15(9):1138-1152. PMC: 5581693. DOI: 10.1158/1541-7786.MCR-17-0003. View

20.

Janoff A, Scherer J . Mediators of inflammation in leukocyte lysosomes. IX. Elastinolytic activity in granules of human polymorphonuclear leukocytes. J Exp Med. 1968; 128(5):1137-55. PMC: 2138566. DOI: 10.1084/jem.128.5.1137. View